EP4110341A2 — A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a raf inhibitor
Assigned to Novartis AG · Expires 2023-01-04 · 3y expired
What this patent protects
The present invention relates to a pharmaceutical combination comprising dabrafenib, an Erk-inhibitor and a RAF inhibitor; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in whic…
USPTO Abstract
The present invention relates to a pharmaceutical combination comprising dabrafenib, an Erk-inhibitor and a RAF inhibitor; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which MAPK pathway inhibition is beneficial, for example, in the treatment of cancers.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.